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Diabetic Cardiomyopathy
A recent article in Circulation' represents an important contribution to the issue raised in a timely editorial2 that questioned the existence of cardiomyopathy in diabetes. The higher collagen concentration in the diabetic heart than in the hypertensive heart is somewhat surprising. Since aging may contribute to this process, data on age-matched controls would be helpful. Moreover, age is a key issue in considering the presence of undiagnosed hypertension thought to exist in more than half of diabetic patients, based on the presence of renal hyaline arteriolosclerosis. The latter has also been reported in aging of the nonhypertensive subject.3 Hence, in the absence of clinical evidence of hypertension or more specific morphological evidence of this disease, the case can be made that findings in the diabetic group are largely attributable to the consequences of chronic hyperglycemia.
van Hoeven and Factor1 have indicated that myocardial fibrosis may contribute to the diastolic dysfunction of hypertensive-diabetic cardiomyopathy. A role for interstitial fibrosis and diminished compliance in diabetes in the absence of hypertension is supported by clinical4 and experimental data.5 Which pathogenetic factor exerts the dominant effect when both are present is problematic, but a combination of risk factors would be expected to further promote cardiac dysfunction. It is noteworthy that mortality early after transmural infarction in patients without prior clinical disease or other risk factors has been reported to be seven times more frequent in diabetics than in nondiabetics.6 This phenomenon has been viewed as related to the presence of antecedent subclinical myopathy and is supported by data from an animal model. 7 Diabetic patients can present with the range of cardiac symptoms attributable to cardiomyopathy in the absence of coronary disease or essential hypertension.8 This varied symptomatology, including heart failure,9,10 has been associated with interstitial fibrosis on endocardial biopsy79 and at postmortem.4,11 
Colchicine Therapy of Recurrent Pericarditis
Guindo and colleagues1 report a significant advance in the management of recurrent pericarditis, probably the most frustrating problem in "pericardiology" as viewed by those of us who see many cases.2 Following their pioneering proposal of 1987,3 they have now successfully treated nine patients without any failures in an open-label prospective study. The difficulty of a classic controlled trial is understandable because these cases are sporadic.
Since the proposal by Rodriguez de la Serna,3 I have had eight patients, all "hooked" on prednisone for varying, though long, periods, in whom the same dose of colchicine has not been uniformly effective. Three patients clearly were improved to the point of successful discontinuation of all therapy. One patient could not tolerate the drug, and the other four were treatment failures, necessitating in these five cases a renewed approach for tapering prednisone while introducing ibuprofen in very large doses. David H. Spodick, MD, DSc Cardiology Division Saint Vincent Hospital Worcester, Massachusetts
